Imidazole Bioisostere Activators of Endopeptidase Neurolysin with Enhanced Potency and Metabolic Stability-Reference-Cited by-同舟云学术

Imidazole Bioisostere Activators of Endopeptidase Neurolysin with Enhanced Potency and Metabolic Stability

Published:2024-03-29 Issue:4 Volume:15 Page:510-517
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Rahman Md. Shafikur¹,Hadi Esfahani Shiva²³,Zhang Yong²,Queen Aarfa¹,Aljarrah Manar³⁴,Kandil Haya³⁴,Baez Andrew²,Abbruscato Thomas J.²⁵,Karamyan Vardan T.³⁶^ORCID,Trippier Paul C.¹⁷^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

2. Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United States

3. Laboratory for Neurodegenerative Disease & Drug Discovery, William Beaumont School of Medicine, Oakland University, Rochester, Michigan 48309, United States

4. Biological and Biomedical Sciences Graduate Program, Oakland University, Rochester, Michigan 48309, United States

5. Center for Blood Brain Barrier Research, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United States

6. Department of Foundational Medical Studies, William Beaumont School of Medicine, Oakland University, Rochester, Michigan 48309, United States

7. UNMC Center for Drug Design and Innovation, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

Funder

National Institute of Neurological Disorders and Stroke

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00009

Reference25 articles.

1. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions

2. Projected Global Trends in Ischemic Stroke Incidence, Deaths and Disability-Adjusted Life Years From 2020 to 2030

3. Non-pharmaceutical therapies for stroke: Mechanisms and clinical implications

4. The Development of Novel Drug Treatments for Stroke Patients: A Review

5. Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need